Dawnrays Pharmaceutical Holdings Ltd. (2348) Stock Statistics & Valuation Metrics

Dawnrays Pharmaceutical Holdings Ltd. has a market cap or net worth of HKD 1.39B. The enterprise value is -HKD 300.73M.

Market Cap

HKD 1.39B

Enterprise Value

-HKD 300.73M

Dawnrays Pharmaceutical Holdings Ltd. has 1,507,025,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,507,025,000

Owned by Insiders

―

Owned by Institutions

―

Dawnrays Pharmaceutical Holdings Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.40%.

Return on Equity (ROE)

0.06

Return on Assets (ROA)

0.05

Return on Invested Capital (ROIC)

5.40%

Return on Capital Employed (ROCE)

0.07

Revenue Per Employee

1.15M

Profits Per Employee

199.23K

Employee Count

1,074

Asset Turnover

0.31

Inventory Turnover

3.12

The current PE Ratio of Dawnrays Pharmaceutical Holdings Ltd. is 5.11. Dawnrays Pharmaceutical Holdings Ltd.’s PEG ratio is 0.20.

PE Ratio

5.11

PS Ratio

1.03

PB Ratio

0.34

Price to FCF

3.94

Price to Operating Cash Flow

3.11

PEG Ratio

0.20

In the last 12 months, Dawnrays Pharmaceutical Holdings Ltd. had revenue of 1.23B and earned 213.97M in profits. Earnings per share was 0.14.

Revenue

1.23B

Gross Profit

557.40M

Operating Income

229.65M

Pretax Income

249.61M

Net Income

213.97M

EBITDA

347.57M

Earnings Per Share (EPS)

0.14

In the last 12 months, operating cash flow was 376.95M and capital expenditures -78.86M, giving a free cash flow of 298.09M billion.

Operating Cash Flow

376.95M

Free Cash Flow

298.09M

Free Cash Flow per Share

0.20

Dawnrays Pharmaceutical Holdings Ltd. pays an annual dividend of HKD 0.05, resulting in a dividend yield of 6.85%

Dividend Per Share

HKD 0.05

Dividend Yield

6.85%

Payout Ratio

40.65%

Free Cash Flow Yield

25.39%

Earnings Yield

19.72%

Beta

0.27

52-Week Price Change

-23.33%

50-Day Moving Average

0.97

200-Day Moving Average

1.03

Relative Strength Index (RSI)

39.48

Average Volume (3m)

333.02K

Dawnrays Pharmaceutical Holdings Ltd. upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 28, 2026

Next Earnings Date

Mar 19, 2027

Ex-Dividend Date

May 27, 2026

Dawnrays Pharmaceutical Holdings Ltd. as a current ratio of 4.64, with Debt / Equity ratio of 2.29%

Current Ratio

4.64

Quick Ratio

4.21

Debt to Market Cap

0.05

Net Debt to EBITDA

-3.13

Interest Coverage Ratio

463.00

In the past 12 months, Dawnrays Pharmaceutical Holdings Ltd. has paid 38.51M in taxes.

Income Tax

38.51M

Effective Tax Rate

0.15

Dawnrays Pharmaceutical Holdings Ltd. EV to EBITDA ratio is -0.32, with an EV/FCF ratio of -0.38.

EV to Sales

-0.10

EV to EBITDA

-0.32

EV to Free Cash Flow

-0.38

EV to Operating Cash Flow

-0.30

Dawnrays Pharmaceutical Holdings Ltd. has HKD 1.59B in cash and marketable securities with HKD 4.48M in debt, giving a net cash position of HKD 1.59B billion.

Cash & Marketable Securities

HKD 1.59B

Total Debt

HKD 4.48M

Net Cash

HKD 1.59B

Net Cash Per Share

HKD 1.05

Tangible Book Value Per Share

HKD 1.94

Gross margin is 47.81%, with operating margin of 20.73%, and net profit margin of 20.29%.

Gross Margin

47.81%

Operating Margin

20.73%

Pretax Margin

24.17%

Net Profit Margin

20.29%

EBITDA Margin

31.71%

EBIT Margin

20.58%

The average price target for Dawnrays Pharmaceutical Holdings Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

6.55%

EPS Growth Forecast

36.62%

Smart Score

4

AI Score

75